New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
08:18 EDTBCS, AZNAstraZeneca, Barclays investors push back on executive pay, Telegraph says
38.5% of AstraZeneca (AZN) shareholders voted against the company's executive pay plan, while 24% of investors voted against Barclays' (BCS) pay plan, reported The Telegraph. "We are disappointed with today's vote. As a priority we will be seeking to understand what concerns lay behind this," said an AstraZeneca spokesman. Reference Link
News For AZN;BCS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
06:46 EDTBCSBarclays appoints KPMG as new auditor
Subscribe for More Information
July 2, 2015
12:22 EDTBCSBrazil investigates banks for exchange rate manipulation
Subscribe for More Information
10:00 EDTAZNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AT&T (T) upgraded to Outperform from Market Perform at Cowen... Acadia Realty Trust (AKR) upgraded to Buy from Neutral at Citi... Alliance Resource Partners (ARLP) upgraded to Buy from Hold at Deutsche Bank... ArcBest (ARCB) upgraded to Peer Perform from Underperform at Wolfe Research... AstraZeneca (AZN) upgraded to Buy from Hold at Berenberg... ConAgra (CAG) upgraded to Overweight from Equal Weight at Morgan Stanley... DuPont Fabros (DFT) upgraded to Buy from Neutral at Citi... EastGroup Properties (EGP) upgraded to Buy from Neutral at Citi... Galaxy Entertainment (GXYEY) upgraded to Hold from Sell at Deutsche Bank... GrubHub (GRUB) upgraded to Outperform from Sector Perform at RBC Capital... HealthSouth (HLS) upgraded to Outperform from Market Perform at JMP Securities... IGM Financial (IGIFF) upgraded to Sector Performer from Underperformer at CIBC... Kennametal (KMT) upgraded to Neutral from Underperform at BofA/Merrill... Kimco Realty (KIM) upgraded to Buy from Neutral at Citi... Kosmos (KOS) upgraded to Outperform at BMO Capital... MGM China (MCHVF) upgraded to Hold from Sell at Deutsche Bank... Regal Entertainment (RGC) upgraded to Neutral from Sell at B. Riley... SL Green Realty (SLG) upgraded to Buy from Neutral at Citi... SQM (SQM) upgraded to Buy from Hold at HSBC... Sands China (SCHYY) upgraded to Hold from Sell at Deutsche Bank... Terex (TEX) upgraded to Neutral from Underperform at BofA/Merrill... United Community Banks (UCBI) upgraded to Outperform from Market Perform at Raymond James... Weingarten Realty (WRI) upgraded to Buy from Neutral at Citi... Willis Group (WSH) upgraded to Neutral from Sell at Goldman... Wynn Macau (WYNMF) upgraded to Hold from Sell at Deutsche Bank.
06:05 EDTBCSBarclays extends cheque imaging to Android users
Barclays announced the extension of its pioneering mobile cheque imaging service to nearly a million more customers, including 500,000 customers with android phones. In another UK first, the service is also now being made available to iPad users. Since the launch of cheque imaging a year ago, nearly three quarters of a million pounds have been deposited by the 30,000 Barclays customers signed up to the mobile cheque imaging tool on their iPhones. The latest roll-out will see this number rise yet higher as more customers are able to benefit from the speed and ease of this time-saving technology. Mobile cheque imaging is available through the Barclays Mobile Banking app and allows customers to pay in a Barclays cheque of up to £500 within minutes of receiving it. Customers simply need to take a photo of the cheque then complete a few quick steps before the funds are immediately available in their current account. Reference Link
05:30 EDTAZNAstraZeneca upgraded to Buy from Hold at Berenberg
Subscribe for More Information
June 30, 2015
10:19 EDTAZNAstraZeneca, Eolas Therapeutics partner on EORA program for smoking cessation
Eolas Therapeutics said that is has entered into a worldwide license and partnership agreement with AstraZeneca on the Eolas Orexin-1 Receptor Antagonist program for smoking cessation and other indications. The EORA program was awarded a Blueprint Neurotherapeutics grant from the National Institutes of Health for the development of the program from the preclinical stage through phase I clinical trials. The total deal potential is in excess of $145M. This includes upfront, clinical and regulatory milestone payments. Additionally, Eolas is eligible to receive royalties on commercial sales.
June 29, 2015
16:13 EDTAZNFibroGen announces receipt of $120M license payment from AstraZeneca
Subscribe for More Information
15:23 EDTBCSBarclays appoints former Dallas Fed President Fisher as senior advisor
Subscribe for More Information
June 28, 2015
17:05 EDTBCSBank regulator probes 'Isdafix' benchmark manipulation, FT says
Subscribe for More Information
June 25, 2015
14:00 EDTAZNAstraZeneca initiated with a Hold at HSBC
Price target GBP 46.40.
June 24, 2015
09:07 EDTAZNCAR-T cancer drug researchers seen as M&A targets, Bloomberg says
Juno Therapeutics (JUNO), Kite Pharma (KITE) and Bluebird Bio (BLUE) are trading well above their IPO levels as takeovers predictions have spurred interest and share increases for the developers of CAR-T gene therapies, said Bloomberg's "Real M&A" column, quoting Dimo Dimov, a professor at the University of Bath’s School of Management, as having said that companies such as Pfizer (PFE), Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) are "closely watching" the firms. Cellectis (CLLS), which is working with Pfizer on its own approach to CAR-T therapy, has said it wants to bring its therapy to market and doesn’t anticipate a sale, the report noted. Reference Link
06:50 EDTAZNAstraZeneca loses top executive Ward-Lilley to Vectura, Reuters reports
Subscribe for More Information
06:40 EDTBCSCalif. utility sues Barclays over electricity price manipulation, Reuters says
Subscribe for More Information
June 23, 2015
12:57 EDTBCSBarclays appoints Nomura’s Sherlund as software banking chair, Bloomberg says
Barclays (BCS) named Richard “Rick” Sherlund as chairman of software banking, Bloomberg reports, citing a company memo. Sherlund comes to the company from Nomura Holdings (NMR) where he worked for the past four years as a managing director and head of U.S. technology research, the report says.
07:31 EDTAZNBIND Therapeutics announces FDA authorization of clinical trial with AZD2811
Subscribe for More Information
06:53 EDTBCSPSAV prepares for IPO that could raise roughly $300M, Bloomberg says
Subscribe for More Information
06:30 EDTBCSBarclays experimenting with blockchain technology, Finextra reports
Subscribe for More Information
06:25 EDTBCSBarclays-Stifel deal marks end of Lehman legacy, Business Insider reports
Subscribe for More Information
06:21 EDTBCSBarclays may sell private equity business to management, Reuters reports
Barclays is in discussions to sell Barclays Natural Resource Investments, its natural resources-focused private equity business, to the unit's management, Reuters reports, citing a source familiar with the situation. Sky News previously reported that the talks are at an "advanced stage" and could be concluded this year. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use